The global market for Lung Cancer Diagnostics was valued at US$2.8 Billion in 2023 and is projected to reach US$4.4 Billion by 2030, growing at a CAGR of 7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Lung Cancer Diagnostics market.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Imaging Tests segment, which is expected to reach US$1.4 Billion by 2030 with a CAGR of 6.7%. The Molecular Tests segment is also set to grow at 7.8% CAGR for the next 7-year period.
- Regional Analysis: Gain insights into the U.S. market, valued at $893.7 Million in 2023, and China, forecasted to grow at an impressive 9.3% CAGR to reach $570.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Lung Cancer Diagnostics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Lung Cancer Diagnostics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Lung Cancer Diagnostics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Biocartis NV, Epigenomics AG, Biodesix, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 48 companies featured in this Lung Cancer Diagnostics market report include:
- Myriad Genetics, Inc.
- F. Hoffmann-La Roche AG
- Biocartis NV
- Epigenomics AG
- Biodesix, Inc.
- Exosome Diagnostics, Inc.
- Admera Health
- Dr Lal PathLabs Ltd.
- Guardant Health, Inc.
- Oncimmune Holding PLC
- Blueprint Genetics OY
- CellMax Life, Inc.
- Circulogene
- BGI Genomics Co Ltd.
- Inivata Ltd.
This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Myriad Genetics, Inc.
- F. Hoffmann-La Roche AG
- Biocartis NV
- Epigenomics AG
- Biodesix, Inc.
- Exosome Diagnostics, Inc.
- Admera Health
- Dr Lal PathLabs Ltd.
- Guardant Health, Inc.
- Oncimmune Holding PLC
- Blueprint Genetics OY
- CellMax Life, Inc.
- Circulogene
- BGI Genomics Co Ltd.
- Inivata Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 605 |
| Published | October 2025 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.8 Billion |
| Forecasted Market Value ( USD | $ 4.4 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
